Fig. 1From: MS275 as Class I HDAC inhibitor displayed therapeutic potential on malignant ascites by iTRAQ-based quantitative proteomic analysisViability of S180, H22 and EAC cells treated with HDACIs. S180 (A), H22 (B) and EAC cells (C) were incubated with 0 μM, 2.5 μM, 5 μM, 10 μM, 20 μM, 40 μM SAHA, MS275 or MC1568 for 48 h. Error bars represent SEMs of at least three independent measurementsBack to article page